M. Brausi Et Al. , "SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS," Annual Meeting of the American-Urological-Association (AUA) , vol.189, California, United States Of America, 2013
Brausi, M. Et Al. 2013. SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS. Annual Meeting of the American-Urological-Association (AUA) , (California, United States Of America).
Brausi, M., Oddens, J., Sylvester, R., Bono, A., Gontero, P., & Turkeri, L., (2013). SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS . Annual Meeting of the American-Urological-Association (AUA), California, United States Of America
Brausi, Maurizio Et Al. "SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS," Annual Meeting of the American-Urological-Association (AUA), California, United States Of America, 2013
Brausi, Maurizio Et Al. "SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS." Annual Meeting of the American-Urological-Association (AUA) , California, United States Of America, 2013
Brausi, M. Et Al. (2013) . "SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS." Annual Meeting of the American-Urological-Association (AUA) , California, United States Of America.
@conferencepaper{conferencepaper, author={Maurizio Brausi Et Al. }, title={SIDE EFFECTS OF BCG IN THE TREATMENT OF INTERMEDIATE AND HIGH RISK TA T1 PAPILLARY CARCINOMA OF THE BLADDER: RESULTS FROM EORTC GU CANCERS GROUP RANDOMIZED STUDY 30962 COMPARING 1/3 DOSE VS FULL DOSE DURING 1 OR 3 YEARS}, congress name={Annual Meeting of the American-Urological-Association (AUA)}, city={California}, country={United States Of America}, year={2013}}